Cloetta AB interim report October-December 2025: Successful year ends with exceptionally strong profit

Cloetta closed the Oct–Dec 2025 quarter with organic sales growth of 1.1% despite net sales declining 2.4% to SEK 2,231m due to a -3.5% FX headwind. Adjusted operating profit rose to SEK 309m (258), reported operating profit was SEK 315m, profit for the period SEK 233m (158) and EPS SEK 0.82 (0.55); cash flow from operations improved to SEK 425m (308) and net debt/EBITDA fell to 0.7x (1.3). The company highlighted strategic decisions including not proceeding with a greenfield plant and restructuring actions, and the Board proposes an increased dividend of SEK 1.40 (1.10) per share, signalling stronger cash generation and de-leveraging.

Analysis

Market structure: Cloetta's quarter signals a winners' setup for branded confectionery and retail pick-&-mix categories — organic sales +1.1% and adjusted EBIT up to SEK 309m with net debt/EBITDA falling to 0.7x. Winners include STO:CLO, national retailers with strong confectionery placement, and bond holders (credit risk down); losers are private-label/value brands and commodity-exposed food producers facing margin pressure. FX (-3.5% in the quarter) is a key demand/price transmission channel: SEK weakness would lift reported sales, while cocoa/sugar spikes would compress margins and feed through to commodity hedges and CDS spreads.

Risk assessment: Tail risks include rapid cocoa/sugar price moves (>15% in 90 days), new sugar/health taxes in core markets, or operational disruption from manufacturing consolidation after cancelling the greenfield plant. Time horizons split: immediate (days) — dividend/ex‑date and Q&A; short (weeks–months) — FX volatility and European retail promotions; long (quarters–years) — strategy execution (Superbrands, marketing, M&A optionality). Hidden dependencies: retailer shelf space, marketing ROI, and any contingent liabilities from the cancelled greenfield; catalysts that would accelerate upside are M&A announcements or continued margin expansion sustaining >SEK 300m adj EBIT per quarter.

Trade implications: Direct play — bias long small-cap branded snacks (STO:CLO) to capture margin recovery and higher dividend, size 2–3% of portfolio with a 12‑month target +20–30% and stop at -12%. Pair trade — long STO:CLO vs short MDLZ (Mondelez, NASDAQ:MDLZ) to isolate small-cap brand upside vs global secular exposure. Options — buy a 6‑month call spread (buy ATM, sell +15% OTM) for a low-cost asymmetric upside; if share price gaps down >8% consider selling 6‑month 5% OTM puts to acquire at a lower basis.

Contrarian angles: Consensus underestimates the financial benefit of not building the greenfield plant (capex avoided and faster ROIC), and may underprice near-term M&A optionality given 0.7x net debt/EBITDA. The market could be underreacting to sustained margin step‑up — if Cloetta proves one more quarter of >SEK 300m adj EBIT the stock should re-rate. Unintended risks: overinvesting in marketing could compress short‑term FCF; a muted retail promotional season could both help margins and hurt top-line volume — monitor 2 next quarterly prints for confirmation.

Key Decisions for Investors

• Establish a 2–3% long position in STO:CLO (Cloetta AB) within 5 trading days; target 20–30% total return over 12 months if adjusted EBIT stays ≥ current run‑rate (~SEK 300m/quarter), trim 50% at +20%, close at -12% stop‑loss.
• Buy a 6‑month call spread on STO:CLO: buy ATM call and sell the 15% OTM call (size = 0.5–1% portfolio notional) to capture upside with limited downside; if price falls >8% instead sell 6‑month 5% OTM puts to establish or lower basis.
• Implement a relative-value pair: long 2% STO:CLO vs short 1% MDLZ (Mondelez, NASDAQ:MDLZ) to play small‑cap branded margin expansion; reassess after 6 months or on first post‑quarter print confirming margin sustainability.
• Hedge/exit triggers: reduce or close long STO:CLO if ICE cocoa or LME sugar futures rise >15% within 90 days, or if a new sugar tax bill gains parliamentary traction in Sweden/UK (material vote within 3–6 months).